LRRK2 and Parkinson disease: The αSyn seed amplification assay (SAA) performed on CSF distinguish patients with PD from healthy controls with high sensitivity and specificity, but results vary depending on the presence of the LRRK2 Gly2019Ser variant, as well as clinical features, particularly hyposmia [57].